Fresh frozen plasma and intravenous immunoglobulin are used as prophylaxis against, and for the treatment of, neonatal infection. It is assumed that any beneficial effect is mediated through the humoral immune factors contained in each preparation. The effect of fresh frozen plasma and intravenous immunoglobulin on humoral immune markers (immunoglobulins and IgG subclasses, complement components and activation products, and C reactive protein) was investigated over a 24 hour period after their randomised administration to 67 infants with suspected infection. Thirty infants without suspicion ofinfection were studied as controls. Compared with control infants, infants with suspected infection had increased concentrations of C reactive protein, reduced concentrations of fibronectin, and increased concentrations of the complement activation marker C3d, but similar concentrations of IgG, IgG subclasses, IgA, and IgM. After intravenous immunoglobulin treatment (500 mg/kg) concentrations of total IgG and all IgG subclasses increased, as did IgA and complement component C4. Concentrations of C reactive protein decreased after intravenous immunoglobulin treatment and were significantly lower than baseline after 24 hours. In contrast, no change in IgG or IgG subclass concentrations occurred after fresh frozen plasma administration. At 24 hours after fresh frozen plasma administration, concentrations of IgA, IgM, and C4 were significantly higher than baseline and serum IgA was significantly higher than in infants tested 24 hours after intravenous immunoglobulin treatment. These results confirm the rational basis for intravenous immunoglobulin treatment but question the value of fresh frozen plasma, particularly in the light of its attendant problems as an untreated blood product. (Arch Dis Child 1994; 70: F182-F187) 
plasma and intravenous immunoglobulin on humoral immune markers (immunoglobulins and IgG subclasses, complement components and activation products, and C reactive protein) was investigated over a 24 hour period after their randomised administration to 67 infants with suspected infection. Thirty infants without suspicion ofinfection were studied as controls. Compared with control infants, infants with suspected infection had increased concentrations of C reactive protein, reduced concentrations of fibronectin, and increased concentrations of the complement activation marker C3d, but similar concentrations of IgG, IgG subclasses, IgA, and IgM. After intravenous immunoglobulin treatment (500 mg/kg) concentrations of total IgG and all IgG subclasses increased, as did IgA and complement component C4. Concentrations of C reactive protein decreased after intravenous immunoglobulin treatment and were significantly lower than baseline after 24 hours. In contrast, no change in IgG or IgG subclass concentrations occurred after fresh frozen plasma administration. At 24 hours after fresh frozen plasma administration, concentrations of IgA, IgM, and C4 were significantly higher than baseline and serum IgA was significantly higher than in infants tested 24 Neonates with severe congenital malformations, viral embryopathy, and those in whom death was considered inevitable were excluded. Previous treatment of the mother with antibiotics did not exclude entry of infants into the study. Infants were enrolled into the study when they had their first suspected episode of infection. After written informed consent was obtained from their parents, the infants were randomly assigned to receive either fresh frozen plasma or intravenous immunoglobulin using a sealed envelope All infants with suspected infection (possible or probable) were screened microbiologically using microscopy and culture examination of swabs taken from the ear, nose, endotracheal DEMOGRAPHIC DATA Seventy seven infants with suspected infection were initially randomised into the study. Ten of these were excluded because of previous treatment with fresh frozen plasma or because they received fresh frozen plasma during the sampling period after having been transfused with intravenous immunoglobulin. Thirty infants without suspicion of infection were enrolled as the control group. Table 1 gives the demographic and laboratory/clinical data on these infants and on the 67 with suspected infection. There was no significant difference in the fresh frozen plasma, intravenous immunoglobulin, and control groups with respect to gestational age, postnatal age, and sex (table 1) . There was, however, a small difference in birthweight between the fresh frozen plasma and intravenous immunoglobulin groups (p=004). The treated groups had a similar distribution of possible or probable infection. Twenty five patients (15 (44%) of the 34 fresh frozen plasma recipients and 10 (30%) of the 33 intravenous immunoglobulin recipients) had proved infection. Nine infants were infected with Escherichia coli (five fresh frozen plasma, four intravenous immunoglobulin), five with Staphylococcus epidermidis (three fresh frozen plasma, two intravenous immunoglobulin), four with Staphylococcus aureus (four fresh frozen plasma, one intravenous immunoglobulin), three with Lancefield group B streptococcus (two fresh frozen plasma, one intravenous immunoglobulin), two with enterobacter (one fresh frozen plasma, one intravenous immunoglobulin), one with citrobacter (fresh frozen plasma), and one with Kiebsiella pneumoniae (intravenous immunoglobulin). Four of these infants were diagnosed as having proved infection on the basis of 3+ positive superficial swabs. One receiving fresh frozen plasma had a pure growth of Lancefield group B streptococcus from the nose, ear, umbilicus, gastric aspirate samples, and a maternal high vaginal swab was 3+ positive for the same organism. In the other three infants (all receiving intravenous immunoglobulin), 3+ positive cultures with pure growth of E coli, citrobacter, and Lancefield group B streptococcus were obtained from the nose, ear, umbilicus, and gastric aspirate samples. In two of these infants cord blood samples were also culture positive, and in the other infant endotracheal tube secretions were culture positive. No differences were observed between fresh frozen plasma and intravenous immunoglobulin recipients with respect to initial leucocyte, neutrophil, and platelet counts (table 1) . There were three deaths in the fresh frozen plasma treated group: one from group B streptococcal septicaemia, severe respiratory distress syndrome, and grade IV intraventricular haemorrhage two days after enrolment into the study; one from S aureus septicaemia, also two days after enrolment; and the third died 30 days after enrolment due to severe bronchopulmonary dysplasia. Similarly, there were three deaths in the intravenous immunoglobulin treated group: one from enterobacter septicaemia on day 9; one from ventricular septal defect and congestive heart failure on day 10; and one from candida septicaemia after two months. No adverse effects were observed with either treatment during or after infusion.
MEASUREMENT OF COMPONENTS OF HUMORAL IMMUNITY
Specimens of 1 ml blood in 10 mmol EDTA and samples from the fresh frozen plasma to be transfused into the infants were collected immediately before the administration of either fresh frozen plasma or intravenous immunoglobulin and from the control group from whom blood was being taken for management purposes. A 1 ml blood sample from the treated infants was also drawn into EDTA at 12 To examine whether changes in humoral markers after treatment with fresh frozen plasma or intravenous immunoglobulin were different in more than in less mature infants, treatment groups were divided according to gestational age (<35 v -35 weeks). Overall, infants <35 weeks' gestation and those 2,35 weeks have similar results to those of the group as a whole. There were some small differences, however. In the fresh frozen plasma treated group, C4 concentrations were higher at 24 hours than at baseline (p<005), but only in infants <35 weeks' gestation. In addition, though concentrations of IgA did not change within the first 12 hours after fresh frozen plasma treatment in infants <35 weeks' gestation, concentrations at 24 hours were significantly higher than at baseline (p<0-05).
In contrast, in infants 335 weeks' gestation, IgA concentrations increased at 12 hours and remained increased compared with baseline (p<0O005 and p<0 05).
In the intravenous immunoglobulin treated group changes seen in infants <35 weeks' and -35 weeks' gestation were identical to each other and to those seen in the undivided group. Table 4 gives the concentrations of IgM, IgA, IgG, IgG subclasses, C reactive protein, C3, C4, C3d, and fibronectin in fresh frozen plasma and intravenous immunoglobulin.
LEVELS OF HUMORAL MARKERS PRESENT IN FRESH FROZEN PLASMA AND INTRAVENOUS IMMUNOGLOBULIN

Discussion
Supplementation of the circulating proteins of neonates prophylactically or after the diagnosis IgG2 (g/l) of suspected infection is carried out with the aim of enhancing humoral immunity. There are two main sources of humoral immune components in current use: fresh frozen plasma and immunoglobulin. Few studies, however, have addressed the question of the efficacy of intravenous immunoglobulin in providing humoral immune components, and none the role of fresh frozen plasma. In this study we showed that intravenous immunoglobulin treatment increases circulating concentrations of all IgG subclasses, as well as increasing IgA and complement C4 concentrations. C reactive protein, a marker of infection in neonates, decreased in the immunoglobulin treated group. In contrast, the administration of fresh frozen plasma had no effect on IgG antibody levels, but resulted in increased concentrations of circulating IgA, IgM, and C4. These results confirm the rational basis for intravenous immunoglobulin treatment but question the value of fresh frozen plasma, particularly in light of its attendant problems as an untreated blood product.
Efficient Most of our patients with suspected infection had low plasma concentrations of fibronectin, which acts as a negative acute phase reactant during infection.6 Fibronectin concentrations did not change after infusion with either fresh frozen plasma or immunoglobulin, in contrast with the study of Caliouli et al. 21 Comparing the concentrations of humoral immune components in fresh frozen plasma and immunoglobulin, it is apparent that the higher IgG content in the latter is responsible for the significant increase in total IgG and its subclasses. To achieve the concentrations of IgG provided by immunoglobulin, an infusion of 30-50 ml/kg of fresh frozen plasma would be required, an unacceptable volume in these infants.
Although it has been suggested that intravenous immunoglobulin treatment is more beneficial in infants of less than 34 weeks' gestation and less than 1500 g birth weight,8 9 13 we did not observe any difference in the effects of intravenous immunoglobulin on markers of humoral immunity in very preterm infants compared with those of older gestational age. We are aware of only one previous study of the effects of fresh frozen plasma on the immune function in neonates.22
This study suggested that fresh frozen plasma enhances neonatal neutrophil motility by providing complement and fibronectin, facilitating movement of these cells to sites of infection. 22 The study did not include control subjects, however, and although the enhancement of neutrophil motility was attributed to complement factors and fibronectin in the fresh frozen plasma, these components were not measured. To our knowledge, our study is the first to show that there are few effects on humoral immunity after fresh frozen plasma administration in neonates, and those changes that occur are of questionable benefit to the host.
Despite the paucity of definitive indications for its use, the administration of fresh frozen plasma has increased in recent years.20 2324 Although well defined indications exist for the use of fresh frozen plasma in single or multiple coagulation deficiencies, indications 
